Eli Lilly Agrees To Buy Morphic For $57 Per Share In Cash, An Aggregate Of Approximately $3.2B, Acquisition To Expand Lilly's Immunology Pipeline With Oral Integrin Therapies
Eli Lilly Agrees To Buy Morphic For $57 Per Share In Cash, An Aggregate Of Approximately $3.2B, Acquisition To Expand Lilly's Immunology Pipeline With Oral Integrin Therapies
伊莉莉製藥同意以現金57美元每股的價格收購Morphic，總計約32億美元，收購將使用口服整合素治療擴大伊莉莉的免疫學研發管線。
Eli Lilly Agrees To Buy Morphic For $57 Per Share In Cash, An Aggregate Of Approximately $3.2B, Acquisition To Expand Lilly's Immunology Pipeline With Oral Integrin Therapies
伊莉莉製藥同意以現金57美元每股的價格收購Morphic，總計約32億美元，收購將使用口服整合素治療擴大伊莉莉的免疫學研發管線。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。